Company Overview
Adicet Bio, Inc. operates as a clinical stage biotechnology firm dedicated to discovering and developing allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and cancer within the United States. The company functions within the Healthcare sector, specifically under the Biotechnology industry, where it focuses on advancing novel cell-based treatments that leverage the immune system's natural capabilities to target pathological conditions. According to available data, the company employs 102 individuals and holds a market capitalization of $62.11M, while its annual revenue is listed as N/A. The absence of reported revenue figures, combined with a market cap of $62.11M, indicates that the company is in an early-stage development phase where value is derived from intellectual property and pipeline potential rather than current sales volume. This scale suggests the organization is still navigating the capital-intensive requirements of clinical trials and regulatory approvals typical for pre-commercial biotechnology entities.
Financial Health
The financial profile of Adicet Bio, Inc. reflects the operational characteristics of a pre-revenue biotechnology company, reporting N/A for revenue and a net income loss of $-116,803,000 for the trailing twelve months. The EBITDA stands at $-115,733,000, and the significant gap between the zero revenue and substantial net income loss reveals a cost structure dominated by research and development expenses, administrative overhead, and clinical trial costs rather than sales commissions. The company generated a free cash flow of $-53,868,752, which indicates a consumption of cash reserves to fund ongoing operations and development activities, thereby limiting immediate financial flexibility for external expansion without further capital raising. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or generated revenue streams to calculate meaningful margins. The balance sheet holds $158.53M in cash against $14.74M in debt, resulting in a debt-to-equity ratio of 9.26, which suggests a highly leveraged capital structure relative to equity but is mitigated by substantial cash holdings that exceed total debt obligations. The current ratio is 7.47, a metric that signifies strong short-term liquidity, demonstrating the company's ability to cover its current liabilities with current assets many times over. Return on Equity is -67.6% and Return on Assets is -37.0%, figures that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common trajectory for early-stage firms investing heavily in future product potential.
Valuation Assessment
Valuation metrics for Adicet Bio, Inc. present a complex picture typical of pre-profitable biotech stocks, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -1.93. The discrepancy between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing the stock based on future earnings expectations that are currently negative, suggesting a reliance on potential future profitability rather than current performance. The price-to-book ratio is 0.44, which indicates that the market values the company at less than its book value, potentially reflecting skepticism about the immediate realization of its clinical pipeline or asset utility. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of 0.64, suggesting the enterprise value is priced very low relative to its earnings before interest, taxes, depreciation, and amortization, though the negative earnings component complicates the traditional interpretation of this multiple. The stock has traded between a 52-Week High of $17.44 and a 52-Week Low of $6.41, placing the current trading range within a wide band that reflects high volatility and market uncertainty regarding the company's commercialization timeline. The Beta is 1.61, a value that signifies the stock is significantly more volatile than the broader market, moving with greater intensity than the average equity and exposing holders to heightened price swings during periods of market turbulence.
Growth & Income
Growth metrics for Adicet Bio, Inc. show Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, indicating that the company is currently in a phase where historical growth rates cannot be calculated due to the lack of established revenue streams or earnings history. Since the company does not pay a dividend, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it does not distribute earnings to shareholders, instead reinvesting all available resources, including its $158.53M cash reserve, back into its clinical stage pipeline and research operations. The absence of a dividend yield confirms that the company prioritizes capital allocation toward drug development and regulatory milestones rather than providing income to investors. Consequently, the overall growth and income profile is defined entirely by the potential future success of its lead product candidate, prulacabtagene leucel, and the company's ability to transition from clinical stages to commercial sales to generate positive revenue growth in the future.